Synaffix Expands the License Agreement with Mersana to Develop ADCs Targeting Cancers for ~$1B
Shots:
- Synaffix is eligible to receive up front & milestones with a total deal value of $1B & is also eligible to receive royalties under the previous collaboration b/w Synaffix & Mersana as reported in 2019
- The collaboration will leverage Synaffix’s GlycoConnect site-specific ADC bioconjugation technology to produce ADC products. Mersana gets the rights for specific ADC targets & get non-exclusive access to use GlycoConnect site-specific ADC bioconjugation technology for 6 additional ADC targets
- Mersana will lead the research, development, manufacturing & commercialization of ADC products & is currently developing two programs XMT-1592 & XMT-1660, based on ADC bioconjugation technology
Ref: PR Newswire | Image: Synaffix
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com